|Bid||4.8500 x 3100|
|Ask||4.8900 x 800|
|Day's Range||4.8900 - 5.0800|
|52 Week Range||4.3430 - 15.8640|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.25|
BOULDER, Colo., January 10, 2022--Inscripta said Ginkgo Bioworks has adopted the Onyx genome engineering platform as part of its commitment to cutting-edge tech in its foundries.
Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicityWATERTOWN, Mass. and BOSTON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses,
NEW YORK, NY / ACCESSWIRE / December 31, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp.